Chimerix, headquartered in RTP, is working on new antiviral medicines for the treatment of life-threatening diseases. Chimerix announced the close of a $45M round of funding earlier this week from a diverse portfolio of investors; they have received $56M in total funding since inception. The most recent financing round will help Chimerix develop two clinical-stage development drugs.
After participating in this round of funding, James Niedel, Managing Director of New Leaf Venture Partners, and Arthur Pappas, Managing Partner of Pappas Ventures, will join Chimerix’s Board of Directors.
Chimerix joined the CED community in 2006. Most recently, Ken Moch, President and CEO, spoke at CED’s Biotech Forum in January.